Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03787680 · ClinicalTrials.gov registry record · Phase 2

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

A Phase 2 study of Prostate Cancer, sponsored by University of Michigan Rogel Cancer Center.

Active
Registry status
Phase 2
Development phase
49
Enrollment target
3
Study locations

NCT03787680 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 49 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03787680, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by University of Michigan Rogel Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
49 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Olaparib
  • DRUG AZD6738

Study Locations (3)

Michigan

  • University of Michigan Hospital - Ann Arbor
  • Wayne State University/Karmanos Cancer Institute - Detroit

Virginia

  • University of Virginia Health System - Charlottesville

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2019-10-31
Est. Completion 2028-08
Phase Phase 2

Sponsor

University of Michigan Rogel Cancer Center

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03787680

The ClinicalTrials.gov registry entry for NCT03787680 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.

NCT03787680 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Virginia.

Frequently Asked Questions

What is clinical trial NCT03787680 about?

NCT03787680 is a clinical study titled "Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)". The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.

What is the current status of trial NCT03787680?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2019-10-31. Estimated completion is 2028-08.

What conditions does trial NCT03787680 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03787680?

The interventions under investigation include: Olaparib (DRUG), AZD6738 (DRUG).

Who is sponsoring clinical trial NCT03787680?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03787680 being conducted?

This trial has 3 study locations across Michigan, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.